Your browser doesn't support javascript.
loading
Global hepatitis C elimination: an investment framework.
Pedrana, Alisa; Howell, Jessica; Scott, Nick; Schroeder, Sophia; Kuschel, Christian; Lazarus, Jeffrey V; Atun, Rifat; Baptista-Leite, Ricardo; 't Hoen, Ellen; Hutchinson, Sharon J; Aufegger, Lisa; Peck, Raquel; Sohn, Annette H; Swan, Tracy; Thursz, Mark; Lesi, Olufunmilayo; Sharma, Manik; Thwaites, John; Wilson, David P; Hellard, Margaret.
Affiliation
  • Pedrana A; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. Electronic address: alisa.pedrana@burnet.edu.au.
  • Howell J; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Department of Gastroenterology, St Vincent's Hospital Melbourne, VIC, Australia.
  • Scott N; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Schroeder S; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Kuschel C; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.
  • Lazarus JV; Barcelona Institute for Global Health, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Atun R; Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA.
  • Baptista-Leite R; Institute of Health Sciences, Universidade Catolica Portuguesa, Lisbon, Portugal; Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.
  • 't Hoen E; Global Health Unit, University Medical Centre Groningen, Groningen, Netherlands; Medicines Law & Policy, Amsterdam, Netherlands.
  • Hutchinson SJ; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, Glasgow, UK.
  • Aufegger L; Centre for Health Policy, Imperial College London, London, UK.
  • Peck R; World Hepatitis Alliance, Imperial College London, London, UK.
  • Sohn AH; TREAT Asia/amfAR-Foundation for AIDS Research Bangkok, Bangkok, Thailand.
  • Swan T; Independent consultant, Barcelona, Spain.
  • Thursz M; Department of Hepatology, Imperial College London, London, UK.
  • Lesi O; College of Medicine, University of Lagos, Lagos, Nigeria.
  • Sharma M; Department of Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar.
  • Thwaites J; Monash Sustainable Development Institute and ClimateWorks Australia, Melbourne, VIC, Australia.
  • Wilson DP; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Hellard M; Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Doherty Institute and Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Departm
Lancet Gastroenterol Hepatol ; 5(10): 927-939, 2020 10.
Article in En | MEDLINE | ID: mdl-32730786
ABSTRACT
WHO has set global targets for the elimination of hepatitis B and hepatitis C as a public health threat by 2030. However, investment in elimination programmes remains low. To help drive political commitment and catalyse domestic and international financing, we have developed a global investment framework for the elimination of hepatitis B and hepatitis C. The global investment framework presented in this Health Policy paper outlines national and international activities that will enable reductions in hepatitis C incidence and mortality, and identifies potential sources of funding and tools to help countries build the economic case for investing in national elimination activities. The goal of this framework is to provide a way for countries, particularly those with minimal resources, to gain the substantial economic benefit and cost savings that come from investing in hepatitis C elimination.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Global Health / Hepatitis C / Disease Eradication / Hepatitis B Type of study: Incidence_studies / Prognostic_studies Limits: Female / Humans / Infant / Newborn / Pregnancy Language: En Journal: Lancet Gastroenterol Hepatol Year: 2020 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Global Health / Hepatitis C / Disease Eradication / Hepatitis B Type of study: Incidence_studies / Prognostic_studies Limits: Female / Humans / Infant / Newborn / Pregnancy Language: En Journal: Lancet Gastroenterol Hepatol Year: 2020 Document type: Article